Review on diagnosis and treatment of focal segmental glomerulosclerosis

Netherlands Journal of Medicine

Volumn 66, Issue 1, 2008, Pages 3-12

  Deegens, J K J ^a   Steenbergen, E J ^a   Wetzels, J F M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diagnosis; Focal segmental glomerulosclerosis; Nephrotic syndrome; Treatment

Indexed keywords

ALENDRONIC ACID; ALPHA INTERFERON; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LITHIUM; PAMIDRONIC ACID; PLACEBO; PODOCIN; PREDNISONE;

ADD ON THERAPY; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FAMILY HISTORY; FOCAL GLOMERULOSCLEROSIS; GENE MUTATION; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIPID METABOLISM; MAXIMUM PERMISSIBLE DOSE; NEPHROTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PODOCYTE; PROGNOSIS; PROTEINURIA; REVIEW; SPONTANEOUS MUTATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS;

EID: 38849142542     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Rich A. A hitherto undescribed vulnerability of the juxtamedullary glomeruli in lipoid nephrosis. Bull Johns Hopkins Hosp 1957;100:173-86.
2. Churg J, Habib R, White RH. Pathology of the nephrotic syndrome in children: a report for the International Study of Kidney Disease in Children. Lancet 1970;760:1299-302.
3. Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997;30:621-31.
4. Pei Y, Cattran DC, Delmore T, et al. Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Am J Med 1987;82:938-44.
5. Korbet S. Primary focal segmental glomerulosclerosis. J Am Soc Nephrol 1998;9:1333-40.
6. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998;54:687-97.
7. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001;12:1164-72.
8. Pascual J, Torrealba J, Myers J, et al. Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate. Osteoporos Int 2007;18:1435-8.
9. Tryggvason K. Unraveling the mechanism of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm. J Am Soc Nephrol 1999;10:2440-5.
10. Lowik MM, Hol FA, Steenbergen EJ, Wetzels JF, van den Heuvel LP. Mitochondrial tRNALeu(UUR) mutation in a patient with steroid-resistant nephrotic syndrome and focal segmental glomerulosclerosis. Nephrol Dial Transplant 2005;20:336-41.
11. Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996;334:878-83.
12. Dantal J, Bigot E, Bogers W, et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994;330:7-14.
13. Deegens JK, Andresclottir MB, Croockewit S, Wetzels JF. Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplant. Transpl Int 2004;17:151-7.
14. Sharma R, Sharma M, McCarthy ET, Ge XL, Savin VJ. Components of normal serum block the focal segmental glomerulosclerosis factor activity in vitro. Kidney Int 2000;58:1973-9.
15. Verani RR, Hawkins EP. Recurrent focal segmental glomerulosclerosis: a pathological study of the early lesion. Am J Nephrol 1986;6:263-70.
16. Smeets B, Te Loeke NA, Dijkman HB, et al. The parietal epithelial cell: a key player in the pathogenesis of focal segmental glomerulosclerosis in Thy-1.1 transgenic mice. J Am Soc Nephrol 2004;15:928-39.
17. Dijkman H, Smeets B, van der Laak J, Steenbergen E, Wetzels J. The parietal epithelial cell is crucially involved in human idiopathic focal segmental glomerulosclerosis. Kidney Int 2005;68:1562-72.
18. Dijkman HB, Weening JJ, Smeets B, et al. Proliferating cells in HIV and pamidronate-associated collapsing focal segmental glomerulosclerosis are parietal epithelial cells. Kidney Int 2006;70:338-44.
19. Smeets B, Dijkman H, Wetzels J, Steenbergen E. Lessons from studies on focal segmental glomerulosclerosis: an important role for parietal epithelial cells? J Pathol 2006;210:263-72.
20. Praga M, Morales E, Herrero J, et al. Absence ofhypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. Am J Kidney Dis 1999;33:52-8.
21. Barisoni L, Szabolcs M, Ward L, D'Agati V. Visceral epithelial cell alterations in focal segmental glomerulosclerosis. Mod Pathol 1994;7:157A.
22. Kambham N, Markowitz G, Valeri A, Lin J, D'Agati V. Obesity-related glomerulopathy: An emerging epidemic. Kidney Int 2001;59:1498-509.
23. Deegeris JK, Dijkman B, Assmann KJ, Wetzels JF. Morphometric analysis of podocytic foot processes in primary and secondary focal and segmental glomerulosclerosis. J Am Soc Nephrol 2004;15:557A.
24. 4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000;24:251-6.
25. Boute N, Gribouval O, Benessy F, et al. NPHS2, encoding the glomerular protein poclocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000;24:349-54.
26. Kestila M, Lenkkeri U, Mannikko M, et al. Positionally cloned gene for a novel glomerular protein - nephrin - is mutated in congenital nephrotic syndrome. Mol Cell 1998;1:575-82.
27. He N, Zahirieh A, Mei Y, et al. Recessive NPHS2 (Poclocin) Mutations Are Rare in Adult-Onset Idiopathic Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol 2007;2:31-7.
28. Caridi G, Bertelli R, Scolari F, et al. Podocin mutations in sporadic focal-segmental glomerulosclerosis occurring in adulthood. Kidney Int 2003;64:365.
29. 4 genes in a series of 33 Italian patients affected by adult-onset nonfamilial focal segmental glomerulosclerosis. Nephron Clin Pract 2005;99:c31-6.
30. Franceschini N, North KE, Kopp JB, McKenzie L, Winkler C. NPHS2 gene, nephrotic syndrome and focal segmental glomerulosclerosis: a HuGE review. Genet Med 2006;8:63-75.
31. van Paassen P, Breda Vriesman PJ, van Rie H, Tervaert JW. Signs and symptoms of thin basement membrane nephropathy: a prospective regional study on primary glomerular disease-The Limburg Renal Registry. Kidney Int 2004;66:909-13.
32. Thomas DB, Franceschini N, Hogan SL, et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 2006;69:920-6.
33. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy ofthe histologic variants. J Am Soc Nephrol 2004;15:2169-77.
34. Korbet S, Schwartz M, Lewis EJ. The prognosis of focal segmental glomerulosclerosis of adulthood. Medicine 1986;65:304-11.
35. Rydell J, Korbet S, Borok R, Schwartz M. Focal segmental glomerulosclerosis in adults: Presentation, course and response to treatment. Am J Kidney Dis 1995;25:534-42.
36. Korbet SM. Clinical picture and outcome of primary focal segmental glomerulosclerosis. Nephrol Dial Transplant 1999;14 Suppl 3:68-73.
37. Korbet S, Schwartz M, Lewis EJ. Primary focal segmental glomerulosclerosis: Clinical course and response to therapy. Am J Kidney Dis 1994;23:773-8.
38. Korbet SM. Primary focal segmental glomerulosclerosis. In: Brady R, Wilcox C, editors. Therapy in Nephrology and Hypertension: A companion to Brenner and Rector's The Kidney. Philadelphia: Saunders, 2003: 223-36.
39. Deegens JKJ, Assmann KJM, Hilbrands LB, et al. Idiopathic focal segmental glomerulosclerosis: clinical criteria identify patients with a favourable prognosis. Neth J Med 2005;63:393-8.
40. Bazzi C, Petrini C, Rizza V, et al. Fractional excretion of IgG predicts renal outcome and response to therapy in primary focal segmental glomerulosclerosis: A pilot study. Am J Kidney DiS 2003;41:328-33.
41. Deegens JKJ, Wetzels JFM. Fractional excretion of high and low molecular weight proteins and outcome in primary focal segmental glomerulosclerosis. Clin Nephrol 2007;in press.
42. Praga M, Hernandez E, Andres G, et al. effects of body-weight loss and captopril treatment on proteinuria associated with obesity. Nephron 1995;70:35-41.
43. Praga M, Hernandez E, Morales E, et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2001;16:1790-8.
44. Szczech L, Edwards L, Sanders L, et al. Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin Nephrol 2002;57:336-41.
45. Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006;21:2809-13.
46. Wali RK, Drachenberg Cl, Papadimitriou JC, Keay S, Ramos E. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. Lancet 1998;352:783-4.
47. Dingli D, Larson DR, Plevak MF, Grande JP, Kyle RA. Focal and segmental glomerulosclerosis and plasma cell proliferative disorders. Am J Kidney Dis 2005;46:278-82.
48. Mallouk A, Pham PT, Pham PC. Concurrent FSGS and Hodgkin's lymphoma: case report and literature review on the link between nephrotic glomerulopathies and hematological malignancies. Clin Exp Nephrol 2006;10:284-9
49. Ruf RG, Lichtenberger A, Karle SM, et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004;15:722-32.
50. Frishberg Y, Rinat C, Megged O, et al. Mutations in NPHS2 encoding podocin are a prevalent cause of steroid-resistant nephrotic syndrome among Israeli-Arab children. J Am Soc Nephrol 2002;13:400-5.
51. Fuchshuber A, Gribouval O, Ronner V, et al. Clinical and genetic evaluation of familial steroid-responsive nephrotic syndrome in childhood. J Am Soc Nephrol 2001;12:374-8.
52. Caridi G, Bertelli R, Di Duca M, et al. Broadening the spectrum of diseases related to podocin mutations. J Am Soc Nephrol 2003;14:1278-86.
53. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologic in Nefrologia). Lancet 1997;349:1857-63.
54. Ruggenenti P, Perna A, Gherard G, et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998;352:1252-6.
55. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-62.
56. K/DOQI Clinical practice Guidelines in Hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:S159-75.
57. Jafar T, Stark P, Schmid C, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139:244-52.
58. K/DOQI Clinical practice Guidelines in Hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:183-205.
59. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939-45.
60. Praga M, Hernandez E, Montoyo C, et al. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1992;20:240-8.
61. Stiles KP, Abbott KC, Welch PG, Yuan CM. Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: a retrospective study in a single clinic. Clin Nephrol 2001;56:89-95
62. Crenshaw G, Bigler S, Salem M, Crook ED. Focal segmental glomerulo-sclerosis in African Americans: effects of steroids and angiotensin converting enzyme inhibitors. Am J Med Sci 2000;319:320-5.
63. Keilani T, Schlueter WA, Levin ML, Battle DC. Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor. Ann Intern Med 1993018:246-54.
64. de Sain-van der Velden MG, Kaysen GA, Barrett HA, et al. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int 1998;53:994-1001.
65. Wanner C, Rader D, Bartens W, et al. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 1993;119:263-9.
66. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993;44:638-42.
67. Curry RC Jr, Roberts WC. Status of the coronary arteries in the nephrotic syndrome. Analysis of 20 necropsy patients aged 15 to 35 years to determine if coronary atherosclerosis is accelerated. Am J Med 1977;63:183-92.
68. Kasiske BL, Velosa JA, Halstenson CE, et al. The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome. Am J Kidney Dis 1990;15:8-15.
69. Spitalewitz S, Porush JG, Cattran D, Wright N. Treatment of hyperlipidemia in the nephrotic syndrome: the effects of pravastatin therapy. Am J Kidney Dis 1993;22:143-50.
70. Rabelink AJ, Hene RJ, Erkelens DW, Joles JA, Koomans HA. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet 1988;2:1335-8.
71. Thomas ME, Harris KP, Ramaswamy C, et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int 1993;44:1124-9.
72. Olbricht CJ, Wanner C, Thiery J, Basten A. Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group. Kidney Int Suppl 1999;71:S113-S116.
73. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
74. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
75. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003;41:605-13.
76. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003;41:565-70.
77. Ponticelli C, Villa M, Banfi G, et al. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney Dis 1999;34:618-25.
78. Cattran D, Rao P. Long term outcome of children and adults with classic focal and segmental glomerulosclerosis. Am J Kidney Dis 1998;32:72-9.
79. Banfi G, Moriggi M, Sabadini E, et al. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 1991;36:53-9.
80. Alexopoulos E, Stangou M, Papagianni A, Pantzaki A, Papadimitriou M. Factors influencing the course and the response to treatment in primary focal segmental glomerulosclerosis. Nephrol Dial Transplant 2000;15:1348-56.
81. Agarwal S, Dash S, Tiwari S, Bhuyan U. Idiopathic adult focal segmental glomerulosclerosis: A clinicopathological study and response to steroids. Nephron 7993;63:168-77.
82. Nagai R, Cattran D, Pei Y. Steroid therapy and prognosis of focal segmental glomerulosclerosis in the elderly. Clin Nephrol 1994;42:18-21.
83. Meyrier A, Noel L, Auriche P, Callard P. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group ofthe Societe de Nephrologie. Kidney Int 1994;45:1446-56.
84. Burgess E. Management of focal segmental glomerulosclerosis: evidence-based recommendations. Kidney Int Suppl 1999;70:S26-S32.
85. Cameron JS. Focal segmental glomerulosclerosis in adults. Nephrol Dial Transplant 2003;18 Suppl 6:vi45-vi51.
86. Ponticelli C, Edefonti A, Ghio L, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant 1993;8:1326-32.
87. Cameron JS. The long term prognosis of patients with focal glomerulosclerosis. Clin Nephrol 1978;10:213-29.
88. Lim V, Sibley R, Spargo B. Adult lipoid nephrosis: clinicopathological correlations. Ann Intern Med 1974;81:314-20.
89. Saint-Hillier Y, Morel-Maroger L, Woodrow D, Richet G. Focal and segmental hyalinosis. Adv Nephrol Necker Hosp 1975;5:67-88.
90. Maher ER, Sweny P, Chappel M, Varghese Z, Moorhead JF. Cyclosporin in the treatment of steroid-responsive and steroid-resistant nephrotic syndrome in adults. Nephrol Dial Transplant 1988;3:728-32.
91. Ponticelli C, Rizzoni G, Edefonti A, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993;43:1377-84.
92. Cattran D, Appel G, Hebert L, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999;56:2220-6.
93. Lee H, Kim H, Kang C, Kim S, Kim M. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Clin Nephrol 1995;43:375-81.
94. Ittel T, Clasen W, Fuhs M, et al. Long-term ciclosporine A treatment in adults with minimal change nephrotic syndrome or focal segmental glomerulosclerosis. Clin Nephrol 1995;44:156-62.
95. Meyrier A, Condamin MC, Broneer D. Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: minimal-change disease and focal-segmental glomerulosclerosis. Collaborative Group of the French Society of Nephrology. Clin Nephrol 1991;35 Suppl 1:S37-42.
96. Walker R, Kincaid-Smith P. The effect of treatment of corticosteroid-resistant idiopathic (primary) focal and segmental hyalinosis and sclerosis (focal glomerulosclerosis) with ciclosporin. Nephron 1990;54:117-21.
97. Smith MC, Austen JL, Carey JT, et al. Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Am I Med 1996;101:41-8.
98. Eustace JA, Nuermberger E, Choi M, et al. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int 2000;58:1253-60.
99. Smith MC, Pawar R, Carey JT, et al. Effect of corticosteroid therapy on human immunodeficiency virus-associated nephropathy. Am J Med 1994;97:145-51.
100. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005;40:1559-85.
101. D'Agati V, Fogo A, Bruijn J, Jennette J. Pathologic classification of focal segmental glomerulosclerosis: A working proposal. Am J Kidney Dis 2004;43:368-82.
102. Stokes MB, Valeri AM, Markowitz GS, D'Agati VD. Cellular focal segmental glomerulosclerosis: Clinical and pathologic features. Kidney Int 2006;70:1783-92.
103. Deegens JKJ, Steenbergen EJ, Borm GF, Wetzels JFM. Pathological Variants of Focal Segmental Glomerulosclerosis in an Adult Dutch Population: Epidemiology and Outcome. Nephrol Dial Transplant 2007;in press.